To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Sep 28, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how certain blood proteins, specifically von Willebrand factor (vWF) and ADAMTS-13, can help predict whether patients with a severe liver condition called acute on chronic liver failure (ACLF) will experience further organ failure. ACLF is a serious condition where the liver suddenly worsens in patients who already have chronic liver disease, and it often leads to complications and high risk of death. Researchers believe that measuring the balance between vWF and ADAMTS-13 might provide important insights into which patients are at greater risk for developing these organ failures.

To participate in this study, you must be over 18 years old and diagnosed with ACLF, but you should not have any extra liver-related organ failures at the time of enrollment. Unfortunately, if you have been on certain medications like blood thinners recently, or if you are pregnant, you won't be able to join. Those who do participate will be monitored closely to see how the levels of these proteins change over time and how that relates to their health outcomes. This research could help doctors better understand and manage ACLF in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - All the patients with age \>18 years who are diagnosed having ACLF fulfilling APASL ACLF criteria and do not have any extrahepatic organ failure at enrollment.
• Exclusion Criteria:
• • 1. Patients on antiplatelet or anticoagulant therapy for at any point of time in last 7 days
• • 2. Pregnant female
• • 3. Patient receiving N-acetyl cysteine (NAC) (interferes with the vWF assay)